Diabetes drug could slash risk of fatal heart condition in one group, scientists reveal

A diabetes drug could help lower the risk of heart failure in certain patients.

A new study published in Nature Medicine analyzed how SGLT2 inhibitor dapagliflozin, a medication used to treat type 2 diabetes, could help prevent heart failure in people with rare genetic variants linked to cardiomyopathy (a progressive disease of the heart muscle).

Using data from the DECLARE-TIMI 58 trial, researchers from Harvard Medical School, Mass General Brigham and MIT looked at more than 12,000...